At the news
? BULLISHIMPACT 8/10 8-K filed Apr 27, 2026 at 08:07 ET
Mirum Pharmaceuticals announced positive Phase 2b results for brelovitug in treating chronic hepatitis delta virus (HDV), with 100% and 75% virologic response rates in the two dose groups versus 0% in the control. The drug was well tolerated, supporting its potential as a single-agent therapy and advancing the program toward Phase 3 topline data in H2 2026.
- Brelovitug met primary endpoint in Phase 2b AZURE-1 study for chronic HDV treatment
- 100% of patients in 300 mg QW arm and 75% in 900 mg Q4W arm achieved virologic response vs. 0% in delayed treatment arm
- Primary composite endpoint (virologic response + ALT normalization) achieved in 45% and 35% of patients, respectively
- Treatment was well tolerated with no grade 3+ treatment-related adverse events and no discontinuations due to AEs
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access